Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6485-90. doi: 10.1016/j.bmcl.2011.08.068. Epub 2011 Aug 28.

Abstract

The discovery of potent N-hydroxyl caprolactam matrix metalloproteinase (MMP) inhibitors (6) based on the natural product Cobactin-T (2) is described. The synthetic method, which utilizes the ring closing metathesis reaction, is compatible to provide complementary (R) and (S) enantiomers. These compounds tested against MMP-2 and 9, show that the R stereochemistry (i.e., 16), which is opposite for that found in the natural product Cobactin-T is >1000-fold more active with IC(50) values of 0.2-0.6nM against both enzymes. The variation in the incorporation of the sulfonamide enzyme recognition element (Ar(2)XAr(1)SO(2)N(R(1)), 6), along with alterations in the RCM/double bond chemistry (R(2)) provided a series of sub nanomolar MMP inhibitors. For example, compounds 16 and 34 were found to be the most potent with IC(50) values against MMP-2 and MMP-9 found to be between 0.2 and 0.6nM with 34 being the most potent compound discovered (MMP-2 IC(50)=0.39nM and MMP-9 IC(50)=0.22nM). Compounds 16 and 34 showed acceptable drug-like properties in vivo with compound 34 showing oral bioavailability.

MeSH terms

  • Azepines / pharmacokinetics
  • Azepines / pharmacology*
  • Biological Availability
  • Cyclization
  • Drug Discovery
  • Inhibitory Concentration 50
  • Matrix Metalloproteinase Inhibitors*
  • Protease Inhibitors / pharmacokinetics
  • Protease Inhibitors / pharmacology*
  • Stereoisomerism

Substances

  • Azepines
  • Matrix Metalloproteinase Inhibitors
  • Protease Inhibitors
  • cobactin T